NCT01692262 - Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Metastatic Castrate-Resistant Prostate Cancer (mCRPC),Efficacy,Safety and Tolerability,Pharmacokinetics,Pharmacodynamics,Tumour Response.

Interventions

DRUG

Intermittent dosing of AZD5363

Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Recruitment suspended and will not be re-opened.

DRUG

Intermittent dosing of AZD5363

Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue to study withdrawal. Recruitment complete.

DRUG

Intermittent dosing of AZD5363

Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue until study drug withdrawal. This part of the study will not be conducted.

Trial Locations (8)

Unknown

Research Site, Sarasota

Research Site, Boston

Research Site, Ann Arbor

Research Site, Hackensack

Research Site, Nashville

Research Site, Cardiff, Wales

Research Site, London

Research Site, Southampton